NEW YORK (Reuters Health) Sept 25 –
The results of a phase I trial show that recombinant human endostatin is safe and well tolerated by patients with refractory solid tumors. Furthermore, the antiangiogenesis agent conferred clinical benefit to 3 of 15 patients included in the trial.
The “unprecedented interest” in endostatin resulting from media reports led to a recruitment process that was “quite different from a typical phase I clinical trial,” Dr. Joseph P. Eder, Jr. of the Dana Farber Cancer Institute in Boston, and colleagues note.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!